Cargando…

Lung microbiota features of stage III and IV non-small cell lung cancer patients without lung infection

BACKGROUND: The microbial community affects the occurrence, development, metastasis and treatment response of cancers. But the detailed role and characteristics of lung microbiota (LM) in non-small cell lung cancer (NSCLC) are not fully known. For NSCLC associated microbiota analysis, it is valuable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Miao, Zhang, Yan, Han, Yaguang, Zhao, Xin, Sun, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904948/ https://www.ncbi.nlm.nih.gov/pubmed/35281416 http://dx.doi.org/10.21037/tcr-22-92

Ejemplares similares

Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection
por: Zhang, Miao, et al.
Publicado: (2022)

Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients
por: Aoki, Takuya, et al.
Publicado: (2019)

Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer
por: Cheruvu, Praveena, et al.
Publicado: (2011)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010)

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience
por: Tiwana, Manpreet Singh, et al.
Publicado: (2013)

Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer
por: Chhatre, Sumedha, et al.
Publicado: (2021)

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021)

Stage IV Non-small Cell Lung Cancer Presenting as Supraventricular Tachycardia
por: Amin, Hina, et al.
Publicado: (2019)

Unanticipated Radiation Replanning for Stage III Non-small Cell Lung Cancer
por: Mushonga, Melinda, et al.
Publicado: (2023)

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
por: Liu, Yang, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer
por: Lu, Xiaojuan, et al.
Publicado: (2022)

Combined Radiomics–Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer
por: Chen, Wenrui, et al.
Publicado: (2022)

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
por: Gao, Yinjie, et al.
Publicado: (2022)

Preliminary exploration of response the course of radiotherapy for stage III non-small cell lung cancer based on longitudinal CT radiomics features
por: Zhang, Ruiping, et al.
Publicado: (2021)

The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study
por: Hsu, Jason C., et al.
Publicado: (2021)

Features of fatigue in patients with early-stage non-small cell lung cancer
por: Huang, Xianping, et al.
Publicado: (2015)

Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features
por: Yang, Nong, et al.
Publicado: (2023)

Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations
por: Li, Xing, et al.
Publicado: (2019)

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer
por: Terakedis, Breanne, et al.
Publicado: (2011)

Therapeutic management options for stage III non-small cell lung cancer
por: Yoon, Stephanie M, et al.
Publicado: (2017)

Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients
por: Urvay, Semiha Elmaci, et al.
Publicado: (2016)

The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer
por: Perdrizet, Kirstin, et al.
Publicado: (2021)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Induction treatment in patients with stage III non-small cell lung cancer
por: Palmero, Ramón, et al.
Publicado: (2021)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2015)

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study
por: Cerqueira, Erica R., et al.
Publicado: (2023)

Outcomes of Image-Guided Moderately Hypofractionated Radiotherapy for Stage III Non-Small-Cell Lung Cancer
por: Zhang, Yang, et al.
Publicado: (2021)

Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients
por: Lee, Joo Ho, et al.
Publicado: (2012)

Alterations of lung microbiota in patients with non-small cell lung cancer
por: Zeng, Wen, et al.
Publicado: (2022)

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma
por: Davies, Rhian Siân, et al.
Publicado: (2017)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer
por: Padole, Atul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3ksvg30ckiqcgqvudi9pu96dg8